Investing in Vermillion, Inc. (AWH)  ➔  Intrinsic value

Prev. close$5.66 
ModelValueUpside
Chepakovich$0.00-100%
Graham-Dodd$0.00-100%
Graham$0.00-100%
Previous Close$5.66  
Valuation MethodValuePotential 
Chepakovich Model$0.00-100%recalculate
Graham-Dodd$0.00-100%recalculate
Graham Formula$0.00-100%recalculate

Latest news

Company description

Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.